(Press-News.org) Even after initial procedures to clear blockages in leg arteries, hospitalizations and associated costs in patients with peripheral artery disease increase as the condition progresses, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
"We are dealing with clinically and economically severe consequences of PAD, a disease which is truly preventable," said Elizabeth Mahoney, Sc.D., the study's lead author. "Our prior research estimated that vascular-related hospitalizations for PAD patients cost the United States $21 billion. Invasive treatment for PAD is costly, and a first invasive procedure becomes a risk factor for further procedures."
PAD, a debilitating condition in which blood flow to the arteries in the legs is obstructed, affects an estimated 8 million Americans, a number expected to increase, said researchers. PAD also is associated with high risk of major cardiovascular events.
For the study, researchers used U.S.-based data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry, an international prospective registry of patients at risk for atherothrombosis, or hardening or narrowing of the arteries due to plaque buildup.
"PAD shares the same risk factors as cardiovascular conditions like stroke and heart attack, but does not always have the dramatic onset," said Mahoney, director of health economics and technology assessment at the Mid America Heart and Vascular Institute of Saint Luke's Hospital in Kansas City, Mo. "Even if it does, it's not treated as seriously."
The prevalence of PAD is known from prior studies to increase from approximately 5 percent at age 50 to 10 percent by 65 and over 25 percent in patients 80 and older, researchers said.
Among 25,763 U.S. participants in the REACH registry, researchers identified 2,396 (9.3 percent) with symptomatic PAD and 213 (0.8 percent) with asymptomatic PAD when they enrolled in 2003 and 2004.
Scientists defined PAD symptoms when claudication was present (characteristic muscle cramping in the lower extremities during exertion) with an ankle-brachial index (ABI) of less than 0.90; a history of lower-limb revascularization such as balloon angioplasty or stenting; or amputation.
The ABI is measured by comparing blood flow in the ankle to that in the arm to detect poor circulation. Patients were considered asymptomatic if they had an ABI of less than 0.90 without symptoms.
Researchers compared the rates of vascular-related hospitalizations and associated costs. One- and two-year follow-up data were available on 1,543 patients with symptomatic PAD and 134 patients with asymptomatic PAD.
Twenty-three percent of asymptomatic and 31 percent symptomatic PAD patients had at least one vascular-related hospitalization during the two-year study. Average cumulative 2-year hospitalization costs per patient were $7,000 for patients with a history of claudication; $7,445 for those with asymptomatic PAD; $10,430 for those with lower limb amputation; and $11,693 for those with a history of revascularization procedures.
"This high rate of hospitalizations would not be acceptable to most patients or physicians as an ideal course of care," says senior author, Alan T. Hirsch, M.D., professor of epidemiology and community health at the University of Minnesota. "No one should assume that the first admission for a PAD procedure is a permanent resolution or 'fix' of the underlying condition."
"In addition to more widespread use of the ABI as an early diagnostic test, preventive strategies, including the adoption of a healthy lifestyle, may help to arrest or stall the progression of the disease and minimize the risk of adverse outcomes."
###
Co-authors are: Kaijun Wang, M.S., Ph.D.; Hong H. Keo, M.D.; Sue Duval, Ph.D.; Kim G. Smolderen, Ph.D.; David J. Cohen, M.D., M.Sc., Ph.D.; Gabriel Steg, M.D.; Deepak L. Bhatt, M.D., M.P.H.; and Alan T. Hirsch, M.D., on behalf of the REACH Registry investigators.
Author disclosures are on the manuscript. Sanofi-aventis and Bristol-Myers Squibb funded the study. REACH is supported by sanofi-aventis, Bristol-Myers Squibb and the Waksman Foundation.
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.
NR10 �(Outcomes/Mahoney)
Additional resources:
Downloadable stock footage, animation, and our image gallery are located at www.heart.org/news under Multimedia.
Stay up to date on the latest news from American Heart Association scientific meetings, including Scientific Sessions 2010, by following us at www.twitter.com/heartnews. We will be tweeting from the conference using hashtag #AHA10News.
END
South San Francisco, CA – October 12, 2010 – Titan Pharmaceuticals, Inc. (TTNP.OB) today announced that data from its previously completed and announced Phase 3 randomized, placebo-controlled clinical trial of Probuphine were published in the Journal of the American Medical Association (JAMA). The article highlights data from the 163-patient trial, which showed that patients receiving Titan's Probuphine implant had significantly less illicit opioid use, experienced fewer symptoms of withdrawal and craving, stayed in treatment longer and had greater overall improvement ...
Researchers at the University of California, San Diego School of Medicine, led by Larry R. Squire, PhD, professor of psychiatry, psychology and neurosciences at UC San Diego and a scientist at the VA San Diego Healthcare System, report that working memory of relational information – where an object is located, for example – remains intact even if key brain structures like the hippocampus are damaged.
The findings, published in the October 13, 2010 issue of The Journal of Neuroscience, run contrary to previous research that suggested spatial information, especially if ...
SALT LAKE CITY—University of Utah (U of U) medical researchers have made an important step in diagnosing autism through using MRI, an advance that eventually could help health care providers indentify the problem much earlier in children and lead to improved treatment and outcomes for those with the disorder.
In a study published on October 15, 2010 in Cerebral Cortex online, researchers led by neuroradiologist Jeffery S. Anderson, M.D., Ph.D., U of U assistant professor of radiology, used MRI to identify areas where the left and right hemispheres of the brains of people ...
Some tiny crustaceans living in clear-water alpine ponds high in Washington state's Olympic Mountains have learned how to cope with the sun's damaging ultraviolet rays without sunblock – and with very little natural pigmentation to protect them.
In fact, in laboratory tests these water fleas, about the size of fruit flies, withstood UV rays much better than the same species of flea taken from a pond less than a mile away, where the water was murkier and thus offered protection.
"The ponds pretty much look the same to us, but the environments are very different for ...
PHILADELPHIA (October 12, 2010)—In an unexpected twist, Fox Chase Cancer Center researchers find that the loss of a single protein, Nedd9, initially slows cancer formation but then makes the tumors that do arise more aggressive. The good news, though, is that the lack of Nedd9 also makes the aggressive tumors more sensitive to a class of drugs that are already used in the clinic.
"If a tumor is able to overcome the loss of this protein, this clearly makes it undergo complicated changes that ultimately select for a more aggressive tumor," says Erica A. Golemis, Ph.D., ...
Researchers at the University of Edinburgh today report a new experimental compound that can improve memory and cognitive function in ageing mice. The compound is being investigated with a view to developing a drug that could slow the natural decline in memory associated with ageing.
With support from a Wellcome Trust Seeding Drug Discovery award, the team has identified a preclinical candidate that they hope to take into human trials within a year.
Many people find they become more forgetful as they get older and we generally accept it as a natural part of the ageing ...
The drug reboxetine is, overall, an ineffective and potentially harmful antidepressant, according to a comprehensive study of the evidence published on bmj.com today.
The study also shows that nearly three quarters of the data on patients who took part in trials of reboxetine were not published until now, and that the published data on the drug overestimate the benefits and underestimate the harms of treatment - all underlining the urgent need for mandatory publication of all clinical trial results.
Reboxetine has been approved for the treatment of major depressive ...
To assess the performance of general practices, it is better to ask patients about their actual experiences of care rather than ask for satisfaction ratings, according to new research published on bmj.com today.
The findings call into question the reliability of using surveys to evaluate practice performance.
Patient surveys are used to assess the performance of doctors and practices, and they increasingly enquire about specific patient experiences (e.g. waiting time for an appointment) as well as overall satisfaction.
In the UK, general practices receive some of ...
In a Canadian first, the Peter Munk Cardiac Centre used a new kind of left ventricular assist device (LVAD) to treat a patient with advanced heart failure. The new device is longer lasting than older generation LVADs and may eliminate the need for a second LVAD – a major drawback with the old technology.
The patient, 61-year-old Marva Lorde of Mississauga, suffered a heart attack in 2007 and underwent several treatments for heart failure – including a 10-day intensive care unit stay, angioplasty and pacemaker implantation –culminating in a cardiac arrest in June 2008.
"I ...
With Halloween and the holiday season fast approaching, many people will be watching their waistlines as they're tempted by a cornucopia of sugary and savory foods. Meanwhile a Georgia Tech College of Computing Ph.D. candidate has shown that playing health-related video games on a mobile device can help adults learn to live more healthfully by making smart diet choices. The finding is published in the paper, "Let's Play! Mobile Health Games for Adults," recently presented at Ubicomp 2010 in Copenhagen, Denmark.
OrderUP! is a different take on the recent trend of health-related ...
